All News
Filter News
Found 808,896 articles
-
AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 ‘Long Haulers’Institutional Review Board Authorizes Public Notification for Potential Enrollment of Subjects
12/24/2020
AIM ImmunoTech Inc. (NYSE American: AIM) announced today that the post-COVID-19 “Long Hauler” portion of the active AMP-511 Expanded Access Program (EAP) protocol received approval from the Institutional Review Board (IRB) for a public notification of potential patient enrollment. Eligible patients enrolled in the trial receive treatment with AIM’s flagship pipeline drug Ampligen. AIM announced in October that the myalgic encephalomyelitis/c
-
INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet's EClinicalMedicine
12/24/2020
Peer-reviewed Phase 1 data shows INO-4800 to be immunogenic in 100% of subjects, inducing neutralizing antibody and/or T cell responses INO-4800 demonstrates favorable safety and tolerability, with no serious adverse events reported Offers best-in-class thermostability, including a five-year projected shelf life at normal refrigeration temperature and no frozen transport or storage requirements
-
Interscope Announces FDA De Novo Marketing Authorization of the EndoRotor® System for Direct Endoscopic Necrosectomy (DEN)
12/24/2020
Interscope, Inc. announced today the receipt of FDA de novo clearance to market its EndoRotor® System in the United States for direct endoscopic necrosectomy (DEN), a minimally invasive treatment
-
Oragenics, Inc. Announces $6.5 Million Registered Direct Offering
12/24/2020
Oragenics, Inc., a company focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic, announced it has entered into definitive agreements with investors for the purchase and sale of 14,444,444 shares of its common stock at a purchase price of $0.45 per share in a registered direct offering.
-
SWK Holdings' Subsidiary, Enteris BioPharma, Receives Second Milestone Payment from Cara Therapeutics
12/24/2020
Second milestone payment related to the development of Oral KORSUVA™ follows initial $2.5 million milestone payment received in October
-
Inotrem’s COVID-19 Phase IIa Clinical Trial Declared “National Priority Research” by the French Government’s Clinical Trial Council
12/24/2020
Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway, announces today that its Phase IIa study of nangibotide, the company’s lead product, for the treatment of severe forms of COVID-19 has been declared “National Priority Research” by the French government steering committee for therapeutic clinical trials and other research (CAPNET). In the context of a substant
-
Greenwich LifeSciences to Ring Nasdaq Opening Bell on December 28
12/24/2020
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, announced that it will ring the Nasdaq opening bell on December 28, 2020, in celebration of its recently completed initial public offering.
-
Acerus Announces Waiver of Q4 Financial Covenant in Credit Agreement
12/24/2020
Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP, OTCQB: ASPCF) today announced that it received a waiver letter from SWK Funding LLC (“SWK”) related to the required Minimum Revenue Covenant for Q4-2020 in its existing credit facility with Acerus. All other terms and conditions in the SWK loan agreement remain unchanged. About Acerus Acerus Pharmaceuticals Corporation is a Canadian-based
-
Foresee Pharmaceuticals Announces Completion of US$47 Million Financing
12/24/2020
Foresee pharmaceuticals (TPEx: 6576.TWO) ("Foresee") announces that it has successfully completed an underwritten public offering of 15,000,000 shares of its common stock to the public at a price of NT$88 per share. The aggregate gross proceeds to Foresee from the offering were approximately US$47 million ( NT$1.32 billion ). The pro
-
Tauriga Sciences Inc. Funds the Entirety of the Master Services Agreement that it Recently Entered Into with CSTI
12/24/2020
Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biote
-
TransMedics to Present at the 39th Annual J.P. Morgan Healthcare Conference
12/24/2020
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that members of the management team will present virtually at the upcoming 39 th Annual J.P. Morgan Healthcare Conference. M
-
Former U.S. Rep. Chris Collins spent less than a year in federal prison for pleading guilty to violating felony insider trading laws when he sat on the board of directors of Innate Therapeutics. On Tuesday, Collins received a pardon from President Donald Trump.
-
Yesterday it was reported that the two companies were working to make more of their vaccine than the 1.3 billion it promised to manufacture in 2021.
-
As a result, the company has decided to unblind the treatment assignments of patients in the trial.
-
In October, the FDA placed a clinical hold on the company’s Huntington’s disease gene therapy before that asset could make its way into the clinic.
-
The new state-of-the-art facility, dubbed the “Factory of the Future,” will span 110,000 square feet and will be located in the city of Wilsonville, Oregon.
-
Biopharma Money on the Move: December 16-22
12/23/2020
A roundup of the latest biopharma companies scooping up cash through IPOs and financing rounds. -
It is already a very Merry Christmas for brand new San Diego-based biotech Neomorph, Inc., which found $109 million under the tree in a Series A financing to advance its proprietary protein degradation platform and programs.
-
If you’re planning on looking for a new job at the beginning of the year, now is the time to start your job search prep.
-
Celcuity Announces Clinical Trial Collaboration with Massachusetts General Hospital and Puma Biotechnology
12/23/2020
Study will evaluate the efficacy and safety of NERLYNX® and FASLODEX® in metastatic HR-positive, HER2-negative breast cancer patients selected by the CELsignia® Test